NDRA News & Events

"During the first quarter, we continued to strengthen the clinical foundation for TAEUS Liver while maintaining disciplined operational execution," said Alexander Tokman, CEO of ENDRA Life Sciences. "The recently announced multi-site validation data demonstrated strong agreement with MRI-PDFF across operators and patient populations. These data reinforce our belief that TAEUS Liver has the potential to deliver a practical, point-of-care solution for the large and growing population affected by steatotic liver disease. We remain focused on advancing our regulatory and commercialization strategy while managing our resources carefully."

Endra Life Sciences announced multi-site clinical validation results for TAEUS Liver that demonstrate "strong" concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independent operators and patient populations. TAEUS Liver's thermoacoustic fat fraction measurement closely tracked MRI-PDFF results for patients along the full spectrum of metabolic dysfunction-associated steatotic liver disease and those with elevated body mass index. "The multi-site data aggregation shows that TAEUS Liver delivers MRI-like liver fat quantification at the point of patient care, with a strong correlation to MRI-PDFF of 0.90 and no meaningful bias. We believe the combination of this performance coupled with TAEUS Liver's portability and low cost could make routine liver fat assessment feasible for the more than two billion people worldwide living with MASLD," said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences.

ENDRA Life Sciences Inc trading halted, volatility trading pause